.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 7,223,748

« Back to Dashboard

Details for Patent: 7,223,748

Title:Pharmaceutical formulations for dry powder inhalers in the form of hard-pellets
Abstract: The invention provides a formulation to be administered as a dry powder for inhalation suitable for efficacious delivery of active ingredients into the low respiratory tract of patients suffering from a pulmonary disease such as asthma. In particular, the invention provides a formulation to be administered as dry powder for inhalation freely flowable, which can be produced in a simple way, is physically and chemically stable and capable of delivering both accurate doses and high fine particle fraction of low strength active ingredients by using a high- or medium resistance device.
Inventor(s): Staniforth; John Nicholas (Parma, IT), Vodden Morton; David Alexander (Parma, IT), Gill; Rajbir (Parma, IT), Brambilla; Gaetano (Parma, IT), Musa; Rossella (Parma, IT), Ferrarini; Lorenzo (Parma, IT)
Assignee: Chiesi Farmaceutici S.p.A. (Parma, IT)
Filing Date:Mar 08, 2005
Application Number:11/073,625
Claims:1. A powder comprising: i) a fraction of fine particles, comprising particles of a physiologically acceptable excipient and particles of magnesium stearate, said fraction of fine particles having a mean particle size of less than 35 .mu.m; ii) a fraction of coarse particles, comprising particles of a physiologically acceptable carrier having a particle size of at least 100 .mu.m; and ii) one or more active ingredient in micronised form selected from the group consisting of budesonide and its epimers, formoterol, TA 2005 and its stereoisomers, beclomethasone dipropionate, their salts and mixtures thereof, wherein: said fraction of fine particles (i) comprises said physiologically acceptable excipient in an amount of 90 to 99 percent by weight and said magnesium stearate in an amount of 1 to 10 percent by weight; and said fraction of fine particles and said fraction of coarse particles are present in a weight ratio of between 1:99 and 40:60.

2. A powder according to claim 1, wherein said active ingredient is the 22 R epimer of budesonide.

3. A powder according to claim 1, wherein said active ingredient is a combination of formoterol or TA-2005 with an agent selected from (a) budesonide and its epimers and (b) beclomethasone dipropionate.

4. A powder according to claim 1, wherein said particles of magnesium stearate partially coat the surface of either said particles of said physiologically acceptable excipient or said particles of said physiologically acceptable carrier.

5. A powder according to claim 1, wherein said fraction of fine particles has a particle size of less than 15 .mu.m.

6. A powder according to claim 1, wherein said particles of said physiologically acceptable carrier have a particle size of at least 175 .mu.m, and said fraction of fine particles comprises 98 percent by weight of particles of said physiologically acceptable excipient and 2 percent by weight of magnesium stearate.

7. A powder according to claim 1, wherein said particles of said physiologically acceptable carrier have a "fissure index" of at least 1.25.

8. A powder according to claim 1, wherein said physiologically acceptable excipient is one or more crystalline sugars.

9. A powder according to claim 1, wherein said physiologically acceptable excipient is .alpha.-lactose monohydrate.

10. A process for making a powder according to claim 1, said process comprising: a) co-micronising particles of said physiologically acceptable excipient and particles of said magnesium stearate to reduce the particle size of said physiologically acceptable excipient and said magnesium stearate and to obtain a mixture in which said particles of said physiologically acceptable excipient are coated with said magnesium stearate; b) spheronising said mixture by mixing said mixture with said particles of said physiologically acceptable carrier to to obtain spheronized particles; and mixing said active ingredient in micronized form with said spheronised particles.

11. A process according to claim 10, wherein said co-micronizing is carried out by milling.

12. A process for making a powder according to claim 1, said process comprising: a) mixing in a high-energy mixer particles of said physiologically acceptable excipient having a starting particle size of less than 35 .mu.m and particles of said magnesium stearate to obtain a mixture in which said particles of said magnesium stearate particles partially coat the surface of said particles of said physiologically acceptable excipient; b) spheronising said mixture by mixing said mixture particles of said physiologically acceptable carrier such that particles of said mixture particles adhere to the surface of said particles of said physiologically acceptable carrier, to obtain spheronized particles; and c) mixing said active ingredient in micronised form with said spheronised particles.

13. A process according to claim 12, wherein said particles of said physiologically acceptable excipient which are mixed with said magnesium stearate have a starting particle size of less than 15 .mu.m.

14. A process of making a powder according to claim 1, said process comprising: a) co-mixing particles of said physiologically acceptable carrier, particles of said magnesium stearate and particles of said physiologically acceptable excipient, to obtain a mixture; b) mixing said active ingredient in micronised form with said mixture, wherein the said particles of said physiologically acceptable carrier have a particle size of at least 175 .mu.m and said co-mixing is carried for at least two hours.

15. A powder comprising: i) a fraction of fine particles, comprising particles of a physiologically acceptable excipient and particles of magnesium stearate, said fraction of fine particles having a mean particle size of less than 35 .mu.m; ii) a fraction of coarse particles, comprising particles of a physiologically acceptable carrier having a particle size of at least 100 .mu.m; and ii) one or more active ingredient in micronised form selected from the group consisting of TA 2005, a stereoisomer of TA 2005, a salt of TA 2005, and mixtures thereof, wherein: said fraction of fine particles (i) comprises said physiologically acceptable excipient in an amount of 90 to 99 percent by weight and said magnesium stearate in an amount of 1 to 10 percent by weight; and said fraction of fine particles and said fraction of coarse particles are present in a weight ratio of between 1:99 and 40:60.

16. A powder according to claim 15, wherein said active ingredient comprises TA 2005.

17. A powder according to claim 16, which further comprises an agent selected from (a) budesonide and its epimers and (b) beclomethasone dipropionate.

18. A powder according to claim 16, wherein said particles of magnesium stearate partially coat the surface of either said particles of said physiologically acceptable excipient or said particles of said physiologically acceptable carrier.

19. A powder according to claim 16, wherein said fraction of fine particles has a particle size of less than 15 .mu.m.

20. A powder according to claim 16, wherein said particles of said physiologically acceptable carrier have a particle size of at least 175 .mu.m, and said fraction of fine particles comprises 98 percent by weight of particles of said physiologically acceptable excipient and 2 percent by weight of magnesium stearate.

21. A powder according to claim 16, wherein said particles of said physiologically acceptable carrier have a "fissure index" of at least 1.25.

22. A powder according to claim 16, wherein said physiologically acceptable excipient is one or more crystalline sugars.

23. A powder according to claim 16, wherein said physiologically acceptable excipient is .alpha.-lactose monohydrate.

24. A process for making a powder according to claim 16, said process comprising: a) co-micronising particles of said physiologically acceptable excipient and particles of said magnesium stearate to reduce the particle size of said physiologically acceptable excipient and said magnesium stearate and to obtain a mixture in which said particles of said physiologically acceptable excipient are coated with said magnesium stearate; b) spheronising said mixture by mixing said mixture with said particles of said physiologically acceptable carrier to obtain spheronized particles; and c) mixing said active ingredient in micronized form with said spheronised particles.

25. A process according to claim 24, wherein said co-micronizing is carried out by milling.

26. A process for making a powder according to claim 16, said process comprising: a) mixing in a high-energy mixer particles of said physiologically acceptable excipient having a starting particle size of less than 35 .mu.m and particles of said magnesium stearate to obtain a mixture in which said particles of said magnesium stearate particles partially coat the surface of said particles of said physiologically acceptable excipient; b) spheronising said mixture by mixing said mixture particles of said physiologically acceptable carrier such that particles of said mixture particles adhere to the surface of said particles of said physiologically acceptable carrier, to obtain spheronized particles; and c) mixing said active ingredient in micronised form with said spheronised particles.

27. A process according to claim 26, wherein said particles of said physiologically acceptable excipient which are mixed with said magnesium stearate have a starting particle size of less than 15 .mu.m.

28. A process of making a powder according to claim 16, said process comprising: a) co-mixing particles of said physiologically acceptable carrier, particles of said magnesium stearate and particles of said physiologically acceptable excipient, to obtain a mixture; b) mixing said active ingredient in micronised form with said mixture, wherein the said particles of said physiologically acceptable carrier have a particle size of at least 175 .mu.m and said co-mixing is carried for at least two hours.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc